EARLY ONSET OF ANTIPRURITIC EFFECTS WITH SERLOPITANT FOR CHRONIC PRURITUS: POST HOC ANALYSIS RESULTS FROM A RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL

被引：0

作者：

Staender, Sonja ^{[1
]}

Yosipovitch, Gil ^{[2
]}

Hirman, Joe ^{[3
]}

Kwon, Paul ^{[4
]}

机构：

[1] Univ Hosp Munster, Dept Dermatol, Ctr Chron Pruritus, Munster, Germany

[2] Univ Miami, Sch Med, Dept Dermatol, Miami Itch Ctr, Miami, FL 33152 USA

[3] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA

[4] Menlo Therapeut Inc, Menlo Pk, CA USA

来源：

ACTA DERMATO-VENEREOLOGICA | 2017年 / 97卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

PP79

引用

页码：1058 / 1058

页数：1

共 50 条

[1] Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
Yosipovitch, Gil
Stander, Sonja
Kerby, Matthew B.
Larrick, James W.
Perlman, Andrew J.
Schnipper, Edward F.
Zhang, Xiaoming
Tang, Jean Y.
Luger, Thomas
Steinhoff, Martin
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 882 - +
[2] SERLOPITANT FOR TREATMENT OF CHRONIC PRURITUS: RESULTS OF A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL
Yosipovitch, Gil
Stander, Sonja
Kerby, Matthew B.
Larrick, James W.
Perlman, Andrew J.
Schnipper, Edward F.
Zhang, Xiaoming
Tang, Jean Y.
Luger, Thomas A.
Steinhoff, Martin
ACTA DERMATO-VENEREOLOGICA, 2017, 97 (08) : 1015 - 1015
[3] Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial
Pariser, David M.
Bagel, Jerry
Lebwohl, Mark
Yosipovitch, Gil
Chien, Elaine
Spellman, Mary C.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (06) : 1314 - 1320
[4] Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial
Staender, Sonja
Kwon, Paul
Hirman, Joe
Perlman, Andrew J.
Weisshaar, Elke
Metz, Martin
Luger, Thomas A.
Azimi, Nooshin
Hutcheson, Nathan
Israel-Hanniford, Davelene
Agbonbhase, Amy
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (05) : 1395 - 1402
[5] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF SERLOPITANT EFFECTS ON MULTIPLE MEASURES OF PRURITUS IN PATIENTS WITH PRURIGO NODULARIS
Staender, Sonja
Kwon, Paul
Luger, Thomas A.
ACTA DERMATO-VENEREOLOGICA, 2017, 97 (08) : 1014 - 1015
[6] Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Noboru Imai
Yuki Isogai
Yoshiyuki Shibasaki
Masami Nakai
Miki Ishida
Xiaoping Ning
Nobuyuki Koga
Neurology and Therapy, 2023, 12 : 1981 - 1991
[7] Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Imai, Noboru
Isogai, Yuki
Shibasaki, Yoshiyuki
Nakai, Masami
Ishida, Miki
Ning, Xiaoping
Koga, Nobuyuki
NEUROLOGY AND THERAPY, 2023, 12 (06) : 1981 - 1991
[8] The neurokinin-1 Receptor-Antagonist Serlopitant has antipruritic Effects in Prurigo nodularis: First Results of a randomized Placebo-controlled Study
Stnder, S.
Kwon, P.
Basta, S.
Luger, T.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 78 - 79
[9] Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial
Okata-Karigane, Utako
Pathmarajah, Pirunthan
Gorell, Emily S.
Sum, Katie
Yekrang, Kiana
Phung, Michelle
Barriga, Melissa
Udrizar, Patricia
Bailey, Irene
Li, Shufeng
Lu, Ying
Tang, Jean Y.
Chiou, Albert S.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024,
[10] Rapid decrease in migraine days with rimegepant: Results from a post hoc analysis of a phase 2/3, randomized, double-blind, placebo-controlled trial
Lipton, R. B.
Croop, R.
Jensen, C. M.
Thiry, A. C.
Kim, E.
Kamen, L.
Coric, V
Goadsby, P. J.
HEADACHE, 2021, 61 : 138 - 139

← 1 2 3 4 5 →